Akt and Clusterin As Biomarkers of Chemotherapeutic Responsiveness
Compositions and methods for identifying cancers resistant to treatment due to the presence of elevated pAKT levels and/or overexpression of AKT. The methods comprise the detection of active phosphorylated (p)AKT in a cell or sample of cells. The methods can further include treating the patient with one or more inhibitors of AKT or clusterin responsive to the detection of binding of the antibody to the activated AKT protein or detection of overexpression of AKT. It is found that treatment with AKT or clusterin inhibitors resensitizes advanced cancers to treatment with chemotherapeutics such as docetaxel.
DJEU JULIE Y [US]; COPPOLA DOMENICO [US]
Type of Offer:
« More Biotech Patents